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Myocardial Energetics and Clinical Response to the Cardiotonic Agent
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WARREN K. LASKEY, MD, JOHN W. HIRSHFELD, JR., MD, FACC, KARL T. WEBER, MD, FACC
Philadelphia. Pennsylvania
Cardiotonic agents may prove useful in the long-term
treatment of chronic heart failure provided myocardial
efficiency is enhanced and clinical status is improved.
Accordingly, the short-term hemodynamic and clinical
response to the phosphodiesterase inhibitor, MDL 17043,
was evaluated. Intravenous increments of 0.05 mg/kg
(maximal total 3 mg/kg) were given to a peak cardiac
output response in 13 patients with New York Heart
Association functional class IV heart failure secondary
to ischemic or myopathic disease. Significant (p < 0.05)
responses at peak effect (1.7 mg/kg) included an increase
in cardiac output (3.5 to 4.6 liters/min) and heart rate
(86 to 90 beats/min) and a decrease in pulmonary cap-
illary wedge (25 to 17 mm Hg), mean arterial (85 to 78
mm Hg) and right atrial (10 to 7 mm Hg) pressures.
Coronary sinus flow (measured in nine patients) in-
creased (122 to 144 mVmin, p < 0.01) as did myocardial
Despite standard medical therapy with digitalis and various
diuretic agents, many patients with chronic heart failure
remain symptomatic at rest or with minimal exertion. These
patients with advanced heart failure require additional med-
ical therapy to improve ventricular pump function and amel -
iorate their symptoms. Vasodilator agents, although pro-
viding acute salutary hemodynamic benefits, have not proven
uniformly effective in the long-term management of these
patients. As a result , a variety of cardiotonic agents with
positive inotropic and, in some cases , vasodilator properties
have been developed in the hope of filling this therapeutic
void (I ) .
MDL 17043, a phosphodiestera se inhibitor with both
positive inotropic and vasodilator properties (2- 4), is a new
agent that improves impaired pump function (2,5); its ability
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oxygen uptake (14.1 to 15.1 ml/min, p < 0.01), whereas
myocardial extraction of oxygen (78 to 72%, p < 0.01)
and lactate (24 to 9%, p < 0.01) decreased with three
patients producing lactate at the time of their peak car-
diac output response. Nine of the 12 patients given long-
term oral therapy improved at least one functional class
at 2 weeks. This improvement was sustained at 20 weeks
in five patients .
Thus, MDL 17043 acutely improves the function of
the failing heart. However, the decrease in oxygen ex-
traction occurring with increased myocardial oxygenup-
take suggests that intracoronary shunting may occur
along with an increase in oxygendemand and contribute
to myocardial anaerobiosis in some patients. Hence, to
assure an optimal response in myocardial energetics to
MIlL 17043, individual dose titration and hemody-
namic monitoring are recommended.
to improve symptomatic status with long-term treatment ,
however, has not been reported . In addition, a major concern
surrounding the use of this and other cardiotonic agents is
their potential to increase myocardial oxygen utilization rel-
ative to oxygen availability. This would result in myocardial
anaerobiosis and adversel y affect cardiac performance. Ac-
cordin gly, our evaluation of MDL 17043 in patients with
advanced heart failure was designed to evaluate the follow-
ing: I) the hemodynamic response to the intravenous admin -
istration of the compound and the corresponding respon se
in myocardial energetics; and 2) the efficacy and safet y of
oral MOL 17043 in the long-term management of these
patient s.
Methods
Study patients. Thirteen patients with congestive heart
failure were studied (Table I). All were in New York Heart
Association functional class IV; 10 patients were so debi -
litated as to be chronically bedridden. All were limited by
dyspnea and fatigue; none had angina. The cause of heart
0735-1097/841$3.00
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Table 1. Data on 13 Study Patients
Case Age (yr) & Sex Cause of Heart Failure Cardiac Rhythm EF (%) LVID (cm)
I 55 M VHO NSR 26 8.1
2 48 M IHO NSR 15 7.2
3 63 M IHO NSR 8
4 60 M IHO NSR 21 6.0
5 69 F IHO NSR 17 6.8
6 69 M IHO NSR 13
7 63 M IHO NSR [3
8 60 M IHO AF 12 6.5
9 48 M IHO NSR [5 6.8
10 75 M VHO AF 10 6.5
II 41 F ICM NSR 23
12 67 F ICM NSR 19 8.2
13 63 M IHO NSR 5.7
Mean 60 16 6.9
±SO ±IO ±5 :±:0.9
lACC Vol. 4. No.5
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AF = atrial fibrillation; EF = ejection fraction; F = female; ICM = idiopathic congestive cardiomyopathy;
IHO = ischemic heart disease; LVID = left ventricular internal dimensions at end-diastole; M = male; NSR
= normal sinus rhythm; VHO = valvular heart disease.
failure was ischemic heart disease in nine patients, idio-
pathic congestive cardiomyopathy in two and severe aortic
or mitral valvular incompetence in two. This was con-
firmed by cardiac catheterization in all but one patient with
idiopathic congestive cardiomyopathy. This patient had no
history of angina or myocardial infarction. The electrocar-
diogram showed no evidence of scarring, and there were
no regional wall motion abnormalities on noninvasive test-
ing. Ten of the patients were male and three were female;
the age range was 41 to 75 years. The mean (± SD) ejection
fraction determined by gated blood pool scan was 16 ± 5%
and the mean (± SD) echocardiographic left ventricular in-
ternal dimension at end-diastole was 6.8 ± 0.8 ern. Ten
patients had normal sinus rhythm and three had atrial
fibrillation.
All patients were hospitalized a minimum of 3 days be-
fore the acute hemodynamic study. During this stabilization
phase, adjustments in diuretic and digitalis dosage were
carried out to maximize standard therapy, whereas all va-
sodilating agents other than captopril were discontinued.
Captopril was continued in four patients because, despite
continued debility, they were thought to have had a bene-
ficial response to this agent. Every attempt was made to
achieve a stable medical regimen to compare with the sub-
sequent clinical response to the investigational drug.
Short-term drug study. Written informed consent was
obtained from all patients. Patients came to the cardiac
catheterization laboratory in the postabsorptive state having
received 5 mg of oral diazapam. A triple lumen thermo-
dilution Swan-Ganz catheter was inserted in the right fem-
oral vein and positioned in the pulmonary artery. A ther-
modilution coronary sinus flow catheter (Wilton-Webster
Laboratories) was inserted into the right basilic vein and
positioned in the coronary sinus just proximal to the insertion
of the most proximal marginal vein. This position was con-
firmed by contrast injection, and a stable position was as-
sured throughout the study by fluorscopy. In addition, care-
ful attention was directed toward the thermodilution signal
to assure that a signal indicative of coronary sinus reflux
did not occur. An arterial catheter was inserted percuta-
neously and positioned in the abdominal aorta.
Baseline arterial, pulmonary artery and coronary sinus
samples were obtained for oxygen content. Arterial and
coronary sinus samples were also obtained for lactate con-
centration. Systemic arterial, pulmonary capillary wedge,
pulmonary artery and right atrial pressures were recorded
in duplicate before the administration of MDL 17043. Ther-
modilution coronary sinus blood flow was measured by the
method of Ganz et al. (6) as previously reported for this
laboratory (7). Cardiac output was calculated by thermo-
dilution and by the Fick principle assuming an oxygen con-
sumption of 3.3 cc/min per kg as previously validated in
our laboratory (8) in patients with class III and IV congestive
heart failure.
MDL /7043 was then administered intravenously in di-
vided doses of 0.5 mg/kg and infused at a rate of 12.5
mg/rnin every 20 minutes. The blood samples and hemo-
dynamic measurements obtained in the baseline state were
repeated immediately and 10 minutes after each dose. Fur-
ther dosing was discontinued when additional medication
failed to increase the cardiac output by 10% or when a
maximal dose of 3 mg/kg was achieved.
Calculated values. The following were derived from
measured variables:
Coronary vascular resistance (units)
Mean arterial pressure
Coronary sinus blood flow
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Rate-pressure product (units) = Systolic arterial pressure
x Heart rate.
Myocardial oxygen consumption (mllmin)
Coronary sinus blood flow x (Myocardial arterial - Coro-
nary sinus oxygen difference).
Assays. Blood for lactate determination was deprotein-
ized in iced 10% prechloric acid and assayed on the same
day using a spectrophotometric technique (9). Normal val-
ues in our laboratory are 3 to 12 mg/dl. Normal myocardial
lactate extraction in our laboratory is 24 ± 5% at rest.
Blood oxygen content was measured by co-oximeter (In-
strumentation Laboratories) precalibrated with human blood.
Clinical evaluation of long-term therapy. On the hos-
pital day after the demonstration of acute hemodynamic
efficacy, patients received an oral dose of MOL 17043
equivalent on an mg/kg basis to the intravenous dose that
produced the peak cardiac output response in the catheter-
ization laboratory, provided that myocardial lactate pro-
duction did not occur. The patients who demonstrated myo-
cardiallactate production at the peak cardiac output response
received the next lower dose of MOL 17043 that did not
result in myocardial lactate production. This dose was ad-
ministered as a liquid suspension of 30 mg/ml at a dosing
interval of 8 hours. Concomitant medications given before
catheterization were reinstituted. The MDL 17043 dose was
subsequently increased in three patients at week 8 or 12
when new information about the bioavailability of oral MOL
17043 became available.
Patients were examined daily by the same investigators
and the degree of dyspnea, orthopnea, fatigue and edema
was assessed. The hospitalization phase of the study con-
tinued until the patient's body weight and medical regimen
had been stable for a minimum of 2 days and they were
walking comfortably in their room. An electrocardiogram
and laboratory battery of blood tests were performed on all
patients before hospital discharge.
Outpatient visits were weekly for 4 weeks and every 2
to 3 weeks thereafter and were conducted by a single in-
vestigator. Clinical evaluation included review of symptoms
and a diary of daily weight and physical activity, physical
examination, electrocardiogram, laboratory blood tests and
urinalysis. Concomitant medications were also recorded.
Statistical analysis. Changes in hemodynamic and
metabolic variables were assessed with the t test for paired
Myocardial lactate extraction (%)
(Arterial lactate - Coronary sinus lactate)
Arterial lactate
Myocardial oxygen extraction (%)
(
Arterial Coronary sinus )
- oxygen content - oxygen content
Arterial oxygen content
x 100%.
x 100%.
data. A probability of less than 0.05 was considered sig-
nificant. All values are expressed as mean ± standard
deviation.
Results
Systemic hemodynamics. The systemic hemodynamic
responses to MOL 17043 at the peak cardiac output response
are summarized in Table 2. The peak increase in cardiac
index (1.9 ± 0.5 to 2.6 ± 0.6 liters/min by Fick mea-
surement [p < 0.001] and 2.1 ± 0.7 to 2.9 ± 0.6 by
thermodilution [p < 0.001]) occurred at an average dose of
1.7 ± 0.6 mg/kg (range 1.0 to 2.5). This was associated
with decreases in pulmonary capillary wedge (25 ± 10 to
17 ± 9 mm Hg, p < 0.05), pulmonary artery systolic (49
± 15 to 41 ± 15 mm Hg, p < 0.01) and right atrial (10
± 5 to 7 ± 4 mm Hg, p < 0.05) pressures as well as in
arterial mean (85 ± 11 to 78 ± II mm Hg, p < 0.05),
systolic (122 ± 19 to 116 ± 18 mm Hg, p < 0.01) and
diastolic (70 ± 12 to 61 ± II mm Hg, p < 0.01) pressures.
In addition, a slight but significant (p < 0.05) increase
occurred in heart rate (86 ± 15 to 90 ± IS beat/min).
Coronary blood flow and myocardial oxygen con-
sumption. These variables were measured in 9 of the 13
patients. One patient refused these measurements and in
another three patients these measurements could not be ob-
tained because of technical considerations. In the nine pa-
tients in whom coronary blood flow was measured, MOL
17043 did not alter the rate-pressure product (10,520 ±
1,120 versus 10,500 ± 1,560 mm Hg beats/min -I). None-
theless, coronary blood flow increased from 122 ± 33 mllmin
in the basal state to 144 ± 35 mllmin (p < 0.0 I) at the
peak elevation in cardiac output (Fig. I). Since coronary
driving pressure (mean arterial pressure) decreased after
MOL 17043 administration, this increase in coronary blood
flow was associated with a decrease in coronary vascular
resistance from 0.78 ± 0.25 to 0.62 ± 0.21 mm Hg/min
per ml- I (p < 0.001).
The baseline arterial oxygen saturation was 93.8 ± 2.9%
and decreased slightly but significantly (p < 0.02) to 92.4
± 3.1 % at peak cardiac output. The baseline coronary sinus
oxygen saturation was 20.9 ± 4.2% and increased to 25.8
± 4. 1% (p < 0.00 I) at peak cardiac output. Therefore,
myocardial oxygen extraction decreased from 78 ± 5 to 72
± 4% (p < 0.01) at peak cardiac output (Fig. 2). Accom-
panying the substantial increment in coronary blood flow,
myocardial oxygen consumption increased slightly, but sig-
nificantly (p < 0.01) from 14.1 ± 4.0 to 15.1 ± 3.8 mllmin
(Fig. 3). At the drug dose just below that giving the peak
cardiac output response, no change was noted in coronary
blood flow (131 ± 31 ml/rnin, p = NS versus baseline) or
myocardial oxygen consumption (14.0 ± 4.0 mllmin, p =
NS versus baseline).
Lactate metabolism. The administration of MDL 17043
resulted in an increase in arterial lactate from 11.3 ± 4.6
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Table 2. Systemic Hemodynamic Response to MOL 17043 in 13 Patients
Optimal Pressure (rnm Hg)
Dose Peak CI HR
Case (mg/kg) (liters/min per m l ) (beats/min) PCWP PASP RAP SAP OAP MAP
I
Pre 1.5 69 15 40 0 140 50 68
Post 1.5 2.5 69 4 25 0 140 40 60
2
Pre 1.8 68 30 46 19 130 78 90
Post 1.0 2.3 74 27 44 15 120 67 82
3
Pre 2,0 80 34 58 14 130 78 86
Post 2,5 2.8 90 25 47 4 112 64 80
4
Pre 2.1 78 5 18 5 130 78 95
Post 1.5 2.5 104 3 13 7 122 80 82
5
Pre 2.2 96 30 45 II 90 60 74
Post 1.5 2,3 96 29 47 8 90 64 74
6
Pre 2.8 96 27 57 8 110 68 84
Post 2,0 3.3 96 16 45 6 103 60 77
7
Pre 1.3 80 39 75 II 150 95 107
Post 2.5 1.6 90 28 75 10 145 80 104
8
Pre 1.6 70 25 68 II 135 78 99
Post 1.5 1.9 68 13 43 6 130 68 86
9
Pre 1.3 110 40 60 16 105 66 79
Post 1.0 2.2 114 23 43 7 105 60 77
10
Pre 1.6 80 27 57 9 130 66 92
Post 2.0 2.3 80 22 48 3 135 55 87
II
Pre 1.7 115 14 30 8 104 64 80
Post 1.0 2.7 113 8 23 8 lOS 54 69
12
Pre 3.0 84 18 45 9 134 58 77
Post 1.0 3.9 84 16 40 8 lIS 50 65
13
Pre 2.4 87 20 50 5 96 65 75
Post 2.5 3.4 96 12 40 4 90 55 67
Mean±SD
Pre 1.9 ± 0.5 86 ± 15 25 ± 10 49 ± 15 10 ± 5 122 ± 19 70 ± 12 85 ± II
Post 1.7 ± 6 2.6 ± 0,6 90 ± 15 17 ± 9 41 ± IS 7 ± 4 116 ± 18 61 ± II 78 ± II
p Value <0.001 <0.05 <0.05 <0.01 <0.05 <0.01 <0,01 <0,05
CI = cardiac index; OAP = diastolic arterial pressure; HR = heart rate; MAP = mean arterial pressure; PASP = pulmonary artery systolic pressure;
pewp = pulmonary capillary wedge pressure; Post = after MOL 17043; Pre = before MOL 17043; RAP = right atrial pressure; SAP = systolic
arterial pressure.
to 13.8 ± 5.7 mg/dl (p < 0.02) and in coronary sinus left ventricular filling pressure. Two of these patients had
lactate from 8.8 ± 4.6 to 12.8 ± 6.0 mg/dl (p < 0.01). ischemic cardiomyopathy and one had idiopathic congestive
Myocardial lactate extraction was 24 ± 4% in the basal cardiomyopathy. Lactate extraction was not altered at the
state, and decreased after MDL 17043 administration to 9 dose of MDL 17043 just below that which resulted in the
± 5% (p < 0.05) (Fig. 4). Three patients developed myo- peak cardiac output response (19.2 ± 15%, p = NS versus
cardiallactate production (that is, venous lactate greater than baseline).
arterial lactate) at the peak drug effect. Additional doses in Clinical status. Figure 5 illustrates the clinical status of
these patients resulted in further lactate production and a the study group over a 24 week period as measured by the
decrease in cardiac output with no change or an increase in New York Heart Association functional classification. Twelve
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Figure 2. Myocardial oxygen extraction in the basal state and at
the peak cardiac output response to MOL 17043. The administra-
tion of MOL 17043 was associated with a significantdecrease in
myocardial oxygenextractionfrom78 ± 5 to 72 ± 4%. Individual
patientsare denoted by number. All patients responded in a similar
fashion.
creased from approximately 1.5 mg/kg every 8 hours to 3.0
mg/kg per dose. Several patients responded to this dose
increase with a return to their previously attained higher
functional class. Thus, 5 of 12 patients had a sustained
improvement in clinical status after 20 weeks of therapy.
This improvement was maintained at week 24 in three of
these five patients (Fig. 5).
Three patients derived little benefit from long-term oral
MDL 17043 therapy. Each of these patients was found to
have myocardial lactate production during the short-term
administration of the drug. One patient died in cardiogenic
shock I week after the start of treatment with the oral prep-
aration. The remaining two patients were discharged from
the hospital, but continued to be severely debilitated; oral
MDL 17043 therapy was continued in both, one of whom
died 2 days later.
The mean duration of treatment for the entire patient
group was 24. I ± 12.9 weeks. Three patients died suddenly
at weeks 17, 24 and 27; four patients died with complica-
tions of severe heart failure at weeks I, 8, II and 33. The
death at week II occurred when the patient was not taking
MDL 17043. One patient withdrew from therapy after 16
weeks of treatment because he believed the experimental
drug was not helping him; he remains alive but is in func-
tional class IV.
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of the 13 patients were taking oral MDL 17043 at a mean
dose of 1.5 ± 0.45 mg/kg every 8 hours. Patient 3 devel-
oped ventricular tachycardia at the end of the hemodynamic
study and was not in the long-term study group. Subsequent
electrophysiologic studies with this patient not taking MDL
17043 suggested that the tachycardia may have been un-
related to the drug. Sustained ventricular tachycardia was
reproducibly initiated by programmed stimulation with dou-
ble extrastimuli from the right ventricular apex and outflow
tract.
After 2 weeks of therapy, 9 of the 12 patients had im-
provement of at least one functional class. By 4 weeks of
MDL 17043 treatment, four patients were in functional class
II and five were in class III; six patients had a reduction in
their concomitant diuretic dosage. The initial clinical im-
provement was sustained in the majority of patients until
approximately 8 weeks of therapy, at which point there was
a gradual deterioration in the symptomatic status of five of
the patients. The deterioration may have been related to
drug tolerance or progression of the underlying disease.
However, new information became available suggesting that
the bioavailability of oral MDL 17043 is between 30 and
60% (personal communications, Merrell Dow Pharmacuet-
icals, Inc.). Accordingly, the MDL 17043 dose was in-
Figure 1. Coronary sinus flow in the basal state (BASE) and at
the peak cardiac output response to MOL 17043 (POST MOL).
The administration of MOL 17043was associatedwitha significant
increase in coronaty sinus flow from 122 ± 33 to 144 ± 35
mllmin. Individual patients are denoted by number. All patients
responded in a similar fashion.
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Figure 4. Myocardial lactate extraction in the basal state and at
the peak cardiac output response to MDL 17043. The administra-
tion of MDL 17043 was associated with a significant decrease in
myocardial lactate extraction from 24 ± 4 to 9 ± 5%. Three
patients (Cases 6, 9 and 12) developed myocardial lactate pro-
duction (negative lactate extraction) after the administration of
MDL 17043. Individual patients are denoted by number.
heart failure and a depressed cardiac output at rest. These
findings are consistent with studies in animal models (2) of
congestive heart failure that have shown a peak increase in
cardiac output with I mg/kg of MOL 17043 and more chron-
otropic effects with little, if any, additional inotropic effects
at higher doses. In our study, the drug-induced increase in
cardiac index was associated with a substantial decrease in
the pulmonary capillary wedge pressure with only minimal
changes in arterial pressure and heart rate. Studies in animal
models (14) of congestive heart failure have also demon-
strated substantial reductions in left atrial pressure with little
change in systolic blood pressure after the administration
of MOL 17043.
Coronary hemodynamic and metabolic effects.
Previous studies (15-17) suggest that myocardial ischemia
may contribute to left ventricular dysfunction in congestive
cardiomyopathy even in the presence of normal coronary
arteries. The increased ventricular wall stress in such pa-
tients increases oxygen demand (18,19), whereas the in-
creased muscle mass and filling pressures may decrease
coronary flow and coronary vascular reserve, particularly
in the subendocardium (17,20-22). Thus, agents that in-
terfere with the distribution of available coronary flow or
that increase oxygen demand by altering contractility could
Discussion
MOL 17043 is an intravenous and oral agent that may
be useful in the short- and long-term treatment of patients
with congestive heart failure (2,5). This agent has been
shown to have both inotropic and systemic vasodilatory
properties (2-4). Both of these effects would serve to in-
crease the output of the failing left ventricle (10, 11). How-
ever, both the inotropic and vasodilatory properties could
cause myocardial ischemic and, thus, result in a paradoxical
reduction in left ventricular function (12,13).
Systemic hemodynamic effects. In the present study,
the administration of 1.0 to 2.5 mg/kg of MDL 17043 in-
creased the cardiac index in patients with severe congestive
Side effects. In general, the drug was well tolerated at
the doses used in this study. Side effects included leuko-
cytosis (four patients) without evidence of local or systemic
infection. Two patients developed moderate hyperglycemia,
one of whom required insulin therapy. Two patients de-
veloped headache that responded easily to an occasional
mild analgesic; one patient complained of frequent bowel
movements that were not described as diarrhea. Four pa-
tients noted an excessive appetite that was out of proportion
to their clinical improvement. None of the patients expe-
rienced anginal chest pain.
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Figure 3. Myocardial oxygen uptake in the basal state and at the
peak cardiac output response to MDL 17043. The administration
of MDL 17043 was associatedwith a significant increase in myo-
cardial oxygen uptake from 14.1 ± 4.0 to 15.1 ± 3.8 mllmin.
Individual patients are denoted by number.
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CI.lFigure 5. Clinical responsesto treatment with oral CI.l
MDL 17043 as assessed by New York Heart As- ~
sociation (NYHA) functional class. Individual pa- 0
tients are denoted by number. Nine of the 12 pa- ~
tients given oral therapyhad an initial improvement Z
of at least one functional class after 2 weeks. The 0
initial clinical improvement was sustained in those ~
patients until 8 weeks, when there was a gradual Z
deterioration in the functional status of fiveof these :)IL.
patients. An increase in the dose in four patients 0(
after week 8 of treatment resulted in an initial fa- %:
>vorable response with a return to the previously Z
attained higher functional class. However, this re-
sponse was transient.Thus, for the group as a whole
at weeks 20 and 24, improvement was maintained
in a total of five (Cases 1,2,5,9 and 13) and three
(Cases I, 5 and 13) patients, respectively.
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potentiate the development of myocardial ischemia in the
failing left ventricle. The net result of such compounds on
the myocardial oxygen supply-demand relation will, there-
fore , depend on their ability to reduce systolic wall stress
by reducing left ventricular filling pressure and chamber
size .
The peak systemic hemodynamic response to MOL 17043
in our study patients was associated with a modest increase
in coronary blood flow and myocardial oxygen consump-
tion . A similar increase in coronary blood flow has been
observed (2) in dogs after the administration of MOL 17043.
Despite the increase in coronary blood flow in our study, a
significant decrease occurred in myocardial lactate extrac-
tion with three patients developing myocardial lactate ex-
traction with three patients developing myocardial lactate
production . It is important to note that the increase in myo-
cardial oxygen demand and decrease in lactate extraction
were associated with a substantial decrease in myocardial
oxygen extraction. This decrease in oxygen extraction sug-
gests inappropriate shunting of blood flow within the myo-
cardium and may be caused by vasodilatory effects of MOL
17043 on the coronary circulation . It has been suggested
(13) that other vasodilating agents may result in intraco-
ronary shunting and potentiate the development of myo-
cardial ischemia in patients with heart failure . The onset of
lactate production in some of our patients could be due to
a maldistribution of coronary flow or to a modest increase
in oxygen demand in the face of a limited supply. Lower
doses of MOL 17043 did not alter coronary blood flow of
result in lactate production. Thus, our data suggest that
WEEKS OF TREATMENT
• DRUG INCREASE
* DRUG WITHDRAWN
D DEATH
lower doses of MOL 17043 may be necessary to avoid these
potential deleterious coronary hemodynamic effects.
Comparison with previous studies in human sub-
jects. A previous study by Uretsky et al. (5) reported more
dramatic changes in blood pressure and cardiac output after
the intravenous administration of MOL 17043 in patients
with congestive heart failure . However, in their study sub-
stantially higher doses of MOL 17043 were administered.
Whether these higher doses would improve myocardial ef-
ficiency (cardiac work relative to oxygen utilization) is un-
known because coronary hemodynamics and myocardial
metabolism were not evaluated. As noted before, our find-
ings suggest that lower doses may be required to avoid the
production of myocardial anaerobiosis . Although most of
the patients in our study had ischemic cardiomyopathy, pa-
tients with idiopathic congestive cardiomyopathy may also
have a decreased coronary reserve (17,20-22) and , there-
fore, might be susceptible to developing myocardial ische-
mia with large doses of the cardiotonic agent, MOL 17043.
Of note is that one of our patients who developed myocardial
lactate production had idiopathic congestive cardiomyopathy.
Arterial oxygenation. The administration of MOL 17043
was associated with a slight but significant (93.8 ± 2.9 to
92.4 ± 3.1%) decrease in the arterial hemoglobin oxygen
saturation . This occurred despite a decrease in the pulmo-
nary capillary wedge pressure. Thus , it is unlikely that wors-
ening pulmonary vascular congestion accounted for the change
in systemic oxygenation. Another potential explanation is
ventilation-perfusion mismatching secondary to nonspecific
vasodilation in the pulmonary vascular bed. Similar de-
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creases in systemic oxygenation have been reported (23)
with other vasodilating agents such as nitroprusside.
Arterial lactate concentration. After the administra-
tion of MDL l7043, there was a significant increase in
arterial lactate concentration. This may be attributable to
one or more mechanisms. As a phophosdiesterase inhibitor,
MDL l7043 could increase glycoloysis and thus increase
systemic lactate production (24). In addition, peripheral nu-
tritive flow may have deteriorated because of shunting of
blood consequent to nonspecific vasodilation (25). Never-
theless, myocardial lactate production is still a valid index
of myocardial anaerobiosis in these patients. During exer-
cise in normal subjects, systemic lactate concentration also
increases, but myocardial lactate production does not occur
(26).
Clinical response. An increase in cardiac output at rest
with a cardiotonic agent does not necessarily imply an im-
provement in effort tolerance and aerobic capacity (8). This
is particularly true if there is a potential for the development
of ischemic left ventricular dysfunction during exercise.
Moreover, if a nonspecific vasodilator is administered then
generalized vasodilation may result in functional shunting
to less metabolically active tissues. As a result, the increased
cardiac output may not result in increased oxygen delivery
to working skeletal muscle during physical activity (25).
Our study included patients with severe decompensated
congestive heart failure. We were unable, therefore, to mea-
sure their maximal oxygen consumption before the admin-
istration MDL 17043. Nonetheless, the acute clinical re-
sponse to oral therapy with this agent was favorable. Most
patients had an increase in their subjective exercise tolerance
as reflected in an improvement of at least one functional
class. This improvement occurred with no other change in
their medical regimen of, in some cases, with a decrease in
concomitant medications (for example, diuretic drugs). The
maintenance of this favorable response beyond 8 to 12 weeks
required an increase in the oral dose of MDL 17043 in some
patients. The failure of most patients to maintain a beneficial
response at 24 weeks may be due to drug tolerance, pro-
gression of their underlying disease or adverse coronary
hemodynamic effects. Further study is necessary to answer
this question.
Clinical implications. MDL 17043 is an orally effective
inotropic and vasodilator agent. Therefore, it may be useful
in the short- and long-term treatment of patients with ad-
vanced congestive heart failure. However, the peak cardiac
output response to the administration of this agent may be
associated with an increase in myocardial oxygen demand
and may produce intracoronary shunting of blood flow con-
sequent to vascular smooth muscle dilation. These effects
may result in myocardial anaerobiosis in selected patients.
Thus, to obtain an optimal response in myocardial energies
to MDL 17043, it may be necessary to administer doses
that result in only moderate increases in the cardiac output.
Additional studies with individual dose titration and hemo-
dynamic monitoring will be necessary to further assess the
value of this agent in the management of patients with
congestive heart failure.
We acknowledge the assistance of Nancy L. Shade in the preparation of
this manuscript and the support provided by the nursing and technical staff
of the cardiac catheterization laboratory.
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